Xenetic Biosciences Inc - Asset Resilience Ratio
Xenetic Biosciences Inc (XBIO) has an Asset Resilience Ratio of 0.43% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Xenetic Biosciences Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2017)
This chart shows how Xenetic Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Xenetic Biosciences Inc asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Xenetic Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read XBIO total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.00K | 0.43% |
| Total Liquid Assets | $67.00K | 0.43% |
Asset Resilience Insights
- Limited Liquidity: Xenetic Biosciences Inc maintains only 0.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xenetic Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Xenetic Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Xenetic Biosciences Inc (2014–2017)
The table below shows the annual Asset Resilience Ratio data for Xenetic Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.35% | $67.00K | $19.16 Million | +0.03pp |
| 2016-12-31 | 0.32% | $67.00K | $20.97 Million | -0.08pp |
| 2015-12-31 | 0.40% | $67.00K | $16.91 Million | -0.01pp |
| 2014-12-31 | 0.40% | $66.00K | $16.32 Million | -- |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, a… Read more